Navigation Links
AstraZeneca and UCL to collaborate to develop regenerative medicines for diabetic retinopathy
Date:9/13/2010

AstraZeneca and UCL (University College London) today announced that they have entered into a collaboration to develop regenerative medicines for diabetic retinopathy (DR).

DR is now the most common cause of vision impairment among those of working age in Western society. The majority of patients with type 1 diabetes will develop retinopathy and about 20-30% will become blind. Moreover, a large number of patients with type 2 diabetes will develop retinopathy as their underlying disease progresses. With the global epidemic of type 2 diabetes, this predicament is set to worsen as over 438 million people are projected to suffer from diabetes and its complications by 2030.

Under the terms of the three-year agreement, AstraZeneca and scientists at the UCL Institute of Ophthalmology will collaborate to identify new therapeutic tools that can modulate the regenerative capacity of stem cells. Dr Marcus Fruttiger, UCL Institute of Ophthalmology, is leading the project and explains that, "These tools could be used either to manufacture transplantable material or to directly stimulate new cell growth in the eye to help restore or improve the vision of those with DR."

"AstraZeneca believes that regenerative medicine offers new opportunities to develop innovative, more effective and safer therapies to benefit patient health. Over the next few years, stem cell technology is likely to contribute to a measurable improvement in our ability to discover and develop candidate drugs, and to target those drugs to the right patient population through a better understanding of the disease process. We are delighted to be combining our drug hunting expertise with the pioneering research ongoing at UCL," said Alan Lamont, Director of Sciences and Technology Alliances at AstraZeneca .

Professor Pete Coffey, UCL Institute of Ophthalmology, adds: "This is a great collaborative opportunity and we're delighted to be working with AstraZeneca to explore the potential of harnessing the regenerative capacity of stem cells to develop a cellular therapy for diabetic retinopathy, which is a major cause of visual impairment and blindness worldwide. AstraZeneca has a proven track record in developing medicines and their involvement in this type of research is very exciting."


'/>"/>

Contact: Dominique Fourniol
d.fourniol@ucl.ac.uk
44-788-183-3274
University College London
Source:Eurekalert

Related medicine news :

1. AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims
2. Freedland Russo Announces $520 Million Settlement Against AstraZeneca
3. Gladstone and Lundbeck collaborate to study neurovascular disease
4. Anakam And Axolotl Collaborate To Deliver A Multi-Factor Authentication Platform For Santa Cruz Health Information Exchange
5. UCLA researchers, US military collaborate to open center for traumatic brain injury
6. Elsevier and InfoDesk collaborate to co-develop federated drug pipeline intelligence solution
7. Carefx to Collaborate with the Cleveland Clinic to Commercialize CCF Business Intelligence Solution
8. Two Hand Therapy Organizations Collaborate on Jam-Packed Educational Weekend
9. BCS Global and Iformata Sign Agreement to Collaborate on the PSVN Initiative to Deliver B2B Video Communications
10. PeopleStreme Collaborates with SkillSoft for Learning Management Content
11. Doctors must collaborate so that patients get full benefit of tamoxifen treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
Breaking Medicine Technology: